Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D07001 + Capecitabine in Advanced Biliary Tract Cancer
NCT06622057Phase 3Recruiting
- Sponsor
- InnoPharmax Inc.
- Start
- Jun 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of D07001-F4 in biliary tract cancer (BTC) (3 arms), sponsored by InnoPharmax Inc. Primary endpoint: Overall Survival at 2 years. Started Jun 2026; status: recruiting.
02
Drugs
D07001-F4
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06622057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06622057.